MY208702A - Methods for treating cancer in models harboring esr1 mutations - Google Patents

Methods for treating cancer in models harboring esr1 mutations

Info

Publication number
MY208702A
MY208702A MYPI2021003130A MYPI2021003130A MY208702A MY 208702 A MY208702 A MY 208702A MY PI2021003130 A MYPI2021003130 A MY PI2021003130A MY PI2021003130 A MYPI2021003130 A MY PI2021003130A MY 208702 A MY208702 A MY 208702A
Authority
MY
Malaysia
Prior art keywords
cancer
methods
estrogen receptor
receptor alpha
treating cancer
Prior art date
Application number
MYPI2021003130A
Other languages
English (en)
Inventor
Tao Nianjun
ARLT Heike
Bihani Teeru
PATEL Hitisha
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of MY208702A publication Critical patent/MY208702A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2021003130A 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations MY208702A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (1)

Publication Number Publication Date
MY208702A true MY208702A (en) 2025-05-25

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021003130A MY208702A (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Country Status (17)

Country Link
US (2) US20220016052A1 (enExample)
EP (1) EP3890835A1 (enExample)
JP (2) JP7497353B2 (enExample)
KR (1) KR20210100135A (enExample)
AU (1) AU2019392908B2 (enExample)
BR (1) BR112021010141A2 (enExample)
CA (1) CA3121918A1 (enExample)
EA (1) EA202191256A1 (enExample)
IL (1) IL283655A (enExample)
JO (1) JOP20210138A1 (enExample)
MA (1) MA54393A (enExample)
MX (1) MX2021006412A (enExample)
MY (1) MY208702A (enExample)
PH (1) PH12021551327A1 (enExample)
SG (1) SG11202105915UA (enExample)
UA (1) UA129588C2 (enExample)
WO (1) WO2020118202A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3834824T3 (fi) * 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
MX393599B (es) * 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco

Also Published As

Publication number Publication date
CA3121918A1 (en) 2020-06-11
EA202191256A1 (ru) 2021-10-06
KR20210100135A (ko) 2021-08-13
MA54393A (fr) 2021-10-13
PH12021551327A1 (en) 2022-04-25
IL283655A (en) 2021-07-29
JP2022511497A (ja) 2022-01-31
JP2024101017A (ja) 2024-07-26
WO2020118202A1 (en) 2020-06-11
EP3890835A1 (en) 2021-10-13
BR112021010141A2 (pt) 2021-08-24
JP7497353B2 (ja) 2024-06-10
AU2019392908A1 (en) 2021-06-10
US20250241875A1 (en) 2025-07-31
UA129588C2 (uk) 2025-06-11
SG11202105915UA (en) 2021-07-29
AU2019392908B2 (en) 2025-02-20
US20220016052A1 (en) 2022-01-20
MX2021006412A (es) 2021-07-21
JOP20210138A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
PH12021551319A1 (en) Methods for treating cancer resistant to cdk4/6 inhibitors
PH12021551290A1 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MY198962A (en) Selective estrogen receptor degraders
MY133571A (en) Compositions and methods for treating conditions responsive to estrogen.
CR20250150A (es) Pyrimidine-fused ring compound, and preparation method therefor and use thereof
MX2021003784A (es) Ligandos degradadores selectivos del receptor de androgenos (sard) y metodos de uso de los mismos.
TW200731973A (en) Pharmaceutical compositions and dosage forms of thalidomide
JP2019520426A5 (enExample)
PH12021550048A1 (en) Selective estrogen receptor degraders.
MX2023011326A (es) Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
PH12022550441A1 (en) Azaheteroaryl compound and application thereof
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
MY208702A (en) Methods for treating cancer in models harboring esr1 mutations
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
PH12021552977A1 (en) Methods of treating urinary system cancers
Ingle et al. Aromatase inhibitors for therapy of advanced breast cancer
Jacamo et al. Effects of CCL2/CCR2 blockade in acute myeloid leukemia
EP3654967A1 (en) Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
ZA202200331B (en) Naltrexone formulation
PH12021551437A1 (en) Estrogen receptor antagonist
MX2024007244A (es) Neuroesteroide para el tratamiento de la enfermedad de huntington.
MX2022007768A (es) Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
WO2019236747A3 (en) Cyclic peptide compounds and methods of use thereof
NZ737825B2 (en) Methods of treating cancer